East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg and 800 mg. Aurobindo Pharma’s Eslicarbazepine Acetate Tablets,  are an AB-rated generic equivalent to the reference listed drug (RLD), Aptiom® Tablets, manufactured by Sumitomo Pharma America, Inc.

Eslicarbazepine Acetate Tablets are indicated for the:

• Treatment of partial-onset seizures in patients 4 years of age and older.